However, in humans, TRP antagonists mainly targeting TRPV1 have been tested for conditions such as dental pain and osteoarthritis, but have shown adverse effects (mainly body temperature dysregulation—hyperthermia), which contributed to the termination of clinical trials [50,90,91]. The gene discussed is TRPV1; the disease is osteoarthritis.